Aprea Therapeutics, Inc.
APRENASDAQHealthcare● Active
$0.73
$-0.01(-0.96%)
Market Cap$4768928
P/E Ratio—
52W High$2.22
52W Low$0.548
Aprea Therapeutics, Inc. (APRE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APRE · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.22
Est. -$0.23 · +4.3%
Revenue
$0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
APRE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.23 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.23 | -$0.22 | +4.3% | $0.00B | — | — |
| ▲ Q1 FY2026 | Mar 16, 2026 | -$0.38 | -$0.32 | +15.8% | $0.00B | $0.00B | +0.0% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.11 | -$0.47 | -327.3% | $0.00B | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.77 | -$0.53 | +31.2% | $0.00B | — | — |
| — Q2 FY2025 | May 14, 2025 | -$0.65 | -$0.66 | -0.9% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$0.69 | -$0.49 | +29.0% | $0.00B | $0.00B | -8.5% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.75 | -$0.64 | +14.7% | $0.00B | $0.00B | +57.6% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.23
EPS Surpr.
+4.3%
Revenue
$0.00B
Q1 FY2026
Mar 16, 2026Beat
EPS Actual
-$0.32
EPS Est.
-$0.38
EPS Surpr.
+15.8%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.47
EPS Est.
-$0.11
EPS Surpr.
-327.3%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.77
EPS Surpr.
+31.2%
Revenue
$0.00B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.66
EPS Est.
-$0.65
EPS Surpr.
-0.9%
Revenue
$0.00B
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.69
EPS Surpr.
+29.0%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.64
EPS Est.
-$0.75
EPS Surpr.
+14.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q2 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q1 FY2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q4 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2026 | $-0.19 | $-0.18 | $-0.18 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +4.3% | $0.90 | $0.88 | -2.22% |
| ▲ Q1 FY2026 | Mar 16, 2026 | +15.8% | $0.74 | $0.76 | +2.73% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -327.3% | $1.32 | $1.26 | -4.55% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +31.2% | $1.69 | $1.70 | +0.59% |
| ▲ Q2 FY2025 | May 14, 2025 | -0.9% | $1.50 | $1.53 | +2.00% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +29.0% | $2.26 | $2.19 | -3.10% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +14.7% | $4.08 | $3.98 | -2.45% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +9.4% | $3.36 | $3.22 | -4.17% |
Q2 FY2026-2.22%
Report Date
May 13, 2026
EPS Beat/Miss
+4.3%
Price Before
$0.90
Price After
$0.88
Q1 FY2026+2.73%
Report Date
Mar 16, 2026
EPS Beat/Miss
+15.8%
Price Before
$0.74
Price After
$0.76
Q4 FY2025-4.55%
Report Date
Nov 12, 2025
EPS Beat/Miss
-327.3%
Price Before
$1.32
Price After
$1.26
Q3 FY2025+0.59%
Report Date
Aug 12, 2025
EPS Beat/Miss
+31.2%
Price Before
$1.69
Price After
$1.70
Q2 FY2025+2.00%
Report Date
May 14, 2025
EPS Beat/Miss
-0.9%
Price Before
$1.50
Price After
$1.53
Q1 FY2025-3.10%
Report Date
Mar 25, 2025
EPS Beat/Miss
+29.0%
Price Before
$2.26
Price After
$2.19
Q4 FY2024-2.45%
Report Date
Nov 7, 2024
EPS Beat/Miss
+14.7%
Price Before
$4.08
Price After
$3.98
Q3 FY2024-4.17%
Report Date
Aug 12, 2024
EPS Beat/Miss
+9.4%
Price Before
$3.36
Price After
$3.22
Avg Beat Reaction-0.95%
Avg Miss Reaction-4.55%
Beat Rate7 / 8 quarters
Largest Move-4.55% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APRE ends December
Aprea Therapeutics, Inc. (APRE) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.22 — beating the analyst consensus of $-0.23 by +4.3%. APRE has beaten EPS estimates for 2 consecutive quarters. The next APRE earnings date is expected around September 1, 2026.
Each quarter, investors track APRE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APRE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APRE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APRE earnings · 5 questionsAprea Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. APRE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APRE historically reports after market close (AMC).
APRE earnings datewhen is APRE earningsAPRE next earnings datewhen does APRE report earningsAPRE earnings calendar
▸ Source: FMP · Aprea Therapeutics, Inc. SEC filings · US GAAP · Aprea Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026